Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144479 | 0.86 | PNMT (0.38) | KDM1AKDM1BPNMT | |
| SCHEMBL28835734 | 0.79 | CHRNB2 (0.40) | KDM1AKDM1BHTR2AHTR2CSLC6A4 | |
| SCHEMBL30016697 | 0.74 | KDM1A (0.44) | KDM1AKDM1BSLC6A2HTR2AHTR2C | |
| SCHEMBL17144876 | 0.71 | KDM1A (0.33) | KDM1AKDM1B | |
| SCHEMBL6971410 | 0.68 | ESR1 (0.45) | PNMTHTR2AHTR2C | |
| SCHEMBL29122834 | 0.67 | OPRM1 (0.39) | — | |
| SCHEMBL14095798 | 0.67 | PNMT (0.37) | PNMTHTR2AHTR2C | |
| SCHEMBL17361476 | 0.67 | FFAR1 (0.45) | — | |
| SCHEMBL17144860 | 0.66 | EDNRB (0.44) | PNMT | |
| SCHEMBL13116629 | 0.65 | CHRNB4 (0.36) | KDM1AKDM1BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126346-B1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-9896434-B2 | Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2018-02-20 | — | — | US | disclosed |
| EP-3126346-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-08 | — | — | EP | disclosed |
| US-20170029405-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-02 | — | — | US | disclosed |
| CN-106132949-A | Substituted indone compound as the GPR119 regulator for the treatment of diabetes, obesity, dyslipidemia and associated conditions | 赛诺菲 | 2016-11-16 | — | — | CN | disclosed |
| WO-2015150563-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029405-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, INSR, GPR65 | KDM1A 1478/4885KDM1B 712/4885PNMT 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.